{"id":"cefuroxime-plus-erythromycin","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"2-5","effect":"Rash"},{"rate":"3-8","effect":"Headache"},{"rate":"1-3","effect":"Hypersensitivity reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cefuroxime is a second-generation cephalosporin that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Erythromycin is a macrolide antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis. Together, they provide synergistic activity against common respiratory bacteria including Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms.","oneSentence":"This combination uses cefuroxime (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and erythromycin (a macrolide) to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:14.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired respiratory tract infections"},{"name":"Bacterial pneumonia with atypical pathogen coverage"}]},"trialDetails":[{"nctId":"NCT05337566","phase":"NA","title":"Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-09-05","conditions":"Infection Post Op, Hysterectomy, Antibiotics","enrollment":2278},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02515565","phase":"NA","title":"Physiotherapy in Patients Hospitalized Due to Pneumonia.","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT01259141","phase":"NA","title":"The Optimization of Mycoplasm Pneumonia Antibiotic Therapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2010-10","conditions":"Mycoplasma Pneumonia","enrollment":208},{"nctId":"NCT02171338","phase":"PHASE4","title":"Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2013-10","conditions":"Pneumonia, Acute Exacerbation of Chronic Obstructive Airways Disease","enrollment":55},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":"Drug-Induced Liver Injury","enrollment":1299056},{"nctId":"NCT00648726","phase":"PHASE3","title":"An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Pneumonia","enrollment":139}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cefuroxime plus erythromycin","genericName":"cefuroxime plus erythromycin","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cefuroxime (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and erythromycin (a macrolide) to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens. Used for Community-acquired respiratory tract infections, Bacterial pneumonia with atypical pathogen coverage.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}